Otter Creek Advisors LLC Makes New $84,000 Investment in Plus Therapeutics, Inc. (NASDAQ:PSTV)

Otter Creek Advisors LLC bought a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTVGet Rating) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 83,901 shares of the company’s stock, valued at approximately $84,000. Otter Creek Advisors LLC owned about 0.38% of Plus Therapeutics at the end of the most recent quarter.

Analyst Upgrades and Downgrades

Several analysts have weighed in on PSTV shares. Maxim Group dropped their target price on shares of Plus Therapeutics to $2.00 in a research report on Thursday, May 26th. HC Wainwright dropped their price objective on shares of Plus Therapeutics from $7.00 to $3.50 and set a “buy” rating on the stock in a report on Friday, July 22nd.

Plus Therapeutics Stock Performance

Shares of PSTV stock traded down $0.02 during trading hours on Friday, hitting $0.48. The company’s stock had a trading volume of 274,877 shares, compared to its average volume of 63,725. The company has a 50 day moving average of $0.55 and a 200 day moving average of $0.76. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.46. Plus Therapeutics, Inc. has a 12-month low of $0.39 and a 12-month high of $2.32.

Plus Therapeutics Company Profile

(Get Rating)

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Further Reading

Want to see what other hedge funds are holding PSTV? Visit to get the latest 13F filings and insider trades for Plus Therapeutics, Inc. (NASDAQ:PSTVGet Rating).

Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with's FREE daily email newsletter.